Live Attenuated Coronavirus Vaccines

Summary

The present invention is directed live, attenuated coronavirus vaccines. The vaccine comprises a viral genome encoding a p59 protein having at mutation at a specific tyrosine residue, and may include other attenuating mutations. Such viruses show reduced growth and pathogenicity in vivo.

Website

U.S. Patent 7,452,542: Live attenuated coronavirus vaccines


Licensing Contact

Mike Villalobos

615.322.6751
Tech ID:
VU0505

Inventors

Mark Denison
Vaccines